Pieter D. Knoester
Erasmus MC
3000 CA Rotterdam
Netherlands
Name/email consistency: high
- A cost-effectiveness decision model for antiepileptic drug treatment in newly diagnosed epilepsy patients. Knoester, P.D., Deckers, C.L., Termeer, E.H., Boendermaker, A.J., Kotsopoulos, I.A., de Krom, M.C., Keyser, T., Renier, W.O., Hekster, Y.A., Severens, H.L. Value. Health (2007)
- Recruitment of a cohort of lamotrigine users through community pharmacists: differences between patients who gave informed consent and those who did not. Knoester, P.D., Belitser, S.V., Deckers, C.L., Keyser, A., Renier, W.O., Egberts, A.C., Hekster, Y.A. Pharmacoepidemiol. Drug. Saf (2005)
- Volume and market share of anti-epileptic drugs in The Netherlands: impact of new drugs. Knoester, P., Deckers, C., van der Vaart, R., Leufkens, B., Hekster, Y. Pharm. World. Sci (2005)
- Cost-effectiveness of add-on lamotrigine therapy in clinical practice. Knoester, P.D., Boendermaker, A.J., Egberts, A.C., Hekster, Y.A., Keyser, A., Severens, J.L., Renier, W.O., Deckers, C.L. Epilepsy Res. (2005)
- Patterns of lamotrigine use in daily clinical practice during the first 5 years after introduction in the Netherlands. Knoester, P.D., Belitser, S.V., Deckers, C.L., Keyser, A., Renier, W.O., Egberts, A.C., Hekster, Y.A. J. Clin. Pharm. Ther (2004)
- Diffusion of the new antiepileptic drug lamotrigine in Dutch clinical practice. Knoester, P.D., Belitser, S.V., Deckers, C.L., Keyser, A., Renier, W.O., Egberts, A.C., Hekster, Y.A. Eur. J. Clin. Pharmacol. (2004)
